Tofacitinib Treatment of Inflammatory Skin Conditions in Patients With Down Syndrome

    July 2022 in “ ˜The œjournal of investigative dermatology/Journal of investigative dermatology ”
    Cory A. Dunnick, A. Rachubinski, B. Enriquez-Estrada … J. Espinosa
    Studysummary In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jidonline.org →
    Discuss this study in the Community →

    Related research 9

    1. Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth Cutis · 2023
    2. The Usefulness and Wellbeing of Tofacitinib in the Treatment of Alopecia Areata Journal of Armed Forces Medical College, Bangladesh · 2022
    3. Resistant Alopecia Areata Treated with Tofacitinib International Journal of Trichology · 2022
    4. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    5. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
    6. Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series Rheumatology and Therapy · 2017
    7. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    8. Alopecia Areata Universalis in a Dog Veterinary dermatology · 2015
    9. PUVA Treatment of Alopecia Areata Totalis and Universalis: A Retrospective Study Australasian journal of dermatology · 2003